Detailansicht

Wissensnetz

Person

Tobias Sinnberg

Biochemiker

Name	Tobias Sinnberg
Ort	Deutschland
Geschlecht	männlich
Akademischer Grad bzw. Titel	Dr. rer. nat. (an der Mathematisch-Naturwissenschaftlichen Fakultät der Univ. Tübingen) (2011)
Beruf	Biochemiker (charakteristischer Beruf)
Datensatztyp	Person
GND-Nummer	1022422243
Datensatz-ID	1022422243
Beteiligt an alle anzeigen Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy Tumour progression stage-dependent secretion of YB-1 stimulates melanoma cell migration and invasion Makrophagen im Melanom – von molekularen Signalen zur therapeutischen Anwendung Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype 6- and 8-Prenylnaringenin, Novel Natural Histone Deacetylase Inhibitors Found in Hops, Exert Antitumor Activity on Melanoma Cells The quest for novel melanoma therapies : casein kinase 1alpha and the canonical Wnt signaling protein beta-catenin in progression and chemoresistance of malignant melanoma

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Tobias Sinnberg

Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy

Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion

Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion

Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy

Tumour progression stage-dependent secretion of YB-1 stimulates melanoma cell migration and invasion

Makrophagen im Melanom – von molekularen Signalen zur therapeutischen Anwendung

Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study

Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs

Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype

6- and 8-Prenylnaringenin, Novel Natural Histone Deacetylase Inhibitors Found in Hops, Exert Antitumor Activity on Melanoma Cells

The quest for novel melanoma therapies : casein kinase 1alpha and the canonical Wnt signaling protein beta-catenin in progression and chemoresistance of malignant melanoma